Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences to $95 from $85 and keeps a Buy rating on the shares. The analyst views the company’s Q4 results as solid. The firm would not be surprised to see stock take a breather following the recent rally but would be a buyer on weakness into a “catalyst rich stretch.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
